ensovibep
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Apr 1, 2021 → Aug 20, 2021
NCT ID
NCT04834856About ensovibep
ensovibep is a phase 2 stage product being developed by Molecular Partners for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04834856. Target conditions include Covid19.
What happened to similar drugs?
4 of 16 similar drugs in Covid19 were approved
Approved (4) Terminated (5) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04834856 | Phase 2 | Completed |
Competing Products
20 competing products in Covid19